MDG-1015

N/A

Report date: 2024/10/28 13:51:28
First In Class

Base Information

Drug NameMDG-1015
Drug Alias NameMDG1015MDG-1015
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocytes stimulantsAnti-NY-ESO-1Anti-HLA-A2
TargetsCancer/testis antigen 1HLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursSoft Tissue Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedigene Ag
China Registration ClassN/A

Develop Information

Active CompaniesMedigene AgMedigene Inc
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursSoft Tissue Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A